Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more
Texas Retina Associates Announces the Retirement of David Callanan, MD
It is with mixed emotions that we announce the retirement of David Callanan, MD, from Texas Retina Associates effective June 30, 2022. He has been caring for patients at our practice since
read more
Dr. Abbey Spoke About Complications of a Compounded Medication Used in “Dropless” Cataract Surgery at the Vit-Buckle Society (VBS) Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, presented “Complications of Compounded Moxifloxacin-Triamcinolone” at the 10th Annual Meeting of the Vit-Buckle Society (VBS) held March 24 – 26, 2022, in Las Vegas. He
read more
Dr. Abbey Reports on Five Emerging Treatments Presented at ARVO 2021
In the July/August 2021 issue of Retina Specialist, Texas Retina Associates’ Ashkan Abbey, MD, published highlights from five compelling retina presentations at the recent Association for Research in Vision and Ophthalmology (ARVO)
read more